SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : DYAX: Dyax Corp. -- Ignore unavailable to you. Want to Upgrade?

To: idos who wrote (178)11/21/2008 3:57:42 PM
From: idos  Respond to of 197
 
FDA has accepted for filing the BLA for DX-88 (ecallantide) for the treatment of acute attacks of HAE and has designated the application for Priority Review. Based on this designation, the FDA Prescription Drug User Fee Act target action date is March 23, 2009.



To: idos who wrote (178)11/22/2008 11:35:40 PM
From: mcbio  Read Replies (1) | Respond to of 197
 
Hasn't Lev already beat them to market and attained the orphan exclusivity? What impact will that have on Dyax?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News